US2019388505A1PendingUtilityA1
Methods and compositions for immunomodulation
Est. expiryJun 2, 2034(~7.8 yrs left)· nominal 20-yr term from priority
A61P 37/06A61P 37/04A61P 37/02A61P 3/10A61P 35/00A61P 29/00A61P 1/04A61P 19/02A61P 17/06C12Y 304/21075A61K 45/06C07K 16/28A61K 38/177A61K 38/482C12Y 304/21A61K 38/1709A61K 2039/505C07K 16/2803C07K 16/18C07K 2317/76A61P 37/00A61K 38/18C07K 14/475A61K 2039/54A61K 39/395
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
Claims
exact text as granted — not AI-modifiedWhat is claimed herein is:
1 . A method of increasing an immune response in a subject in need thereof, the method comprising administering one or more of a Sema3F inhibitor or NRP-2 inhibitor or Plexin A1 inhibitor to the subject.
2 . The method of claim 1 , wherein the Sema3F inhibitor is an anti-Sema3F antibody reagent.
3 . The method of claim 1 , wherein the NRP-2 inhibitor is an anti-NRP-2 antibody reagent.
4 . The method of claim 1 , wherein the Sema3F inhibitor is a soluble NRP-2 receptor.
5 . The method of claim 4 , wherein the Sema3F inhibitor is a soluble fragment of the NRP-2 receptor comprising at least one domain selected from the group consisting of:
the A1, the A2, the B1 or the B2 domain.
6 . The method of claim 1 , wherein the Sema3F inhibitor is a furin-like polypeptide or a nucleic acid encoding a furin-like polypeptide.Join the waitlist — get patent alerts
Track US2019388505A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.